No small group with a particular rare genetic mutation can raise the mountains of cash required to develop a drug and take it through clinical trials. Onno Faber, who has a rare disease himself, is harnessing the power of the collective to further pharma research. By combining the power of patients’ and families’ many lonely efforts-effectively turning them into tiny, virtual biotech startups-he aims to disrupt the rigged game of drug development for rare diseases.
